CTKB

#2816
Cytek Biosciences, Inc. - Common Stock
4.6 0 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
4.57
4.60
Intervallo Annuale
3.28
6.18
Variazione giornaliera
-1.71%
Variazione Mensile
+6.73%
Variazione di 6 mesi
+3.60%
Variazione Annuale
+12.20%
Chiusura Precedente
4.6 8
Open
4.5 8
Minimo
4.5 7
Massimo
4.6 0
Volume
90
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, 21 Aug 2026
Cytek Biosciences, Inc. current report, 21 August 2026
8-K
Current report, Q3 FY2026
Cytek Biosciences, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Cytek Biosciences, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Cytek Biosciences, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Cytek Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Cytek Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Cytek Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Cytek Biosciences, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Cytek Biosciences, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Cytek Biosciences, Inc. current report, Q1 FY2026
8-K

Cytek Biosciences, Inc. current report, Q2 FY2026

Full document

Cytek Biosciences, Inc. (CTKB) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K covers the results of the 2026 Annual Meeting of Stockholders held on June 10, 2026. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol CTKB.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.

Material Changes and Voting Results

As of the record date (April 13, 2026), 129,142,587 shares were outstanding. Approximately 86.1% of outstanding shares (111,161,490 shares) were present or represented by proxy at the meeting. The following matters were approved:

  • Election of Class II Directors: All three nominees were elected to serve until the 2029 annual meeting.
    • Glenn P. Muir: 79,599,103 votes For; 5,894,350 votes Withheld.
    • Ming Yan, Ph.D.: 76,741,063 votes For; 8,752,390 votes Withheld.
    • Vera Imper, Ph.D.: 64,769,976 votes For; 20,723,477 votes Withheld.
  • Executive Compensation (Say-on-Pay): The advisory vote on executive compensation for the year ended December 31, 2025, was approved with 84,794,380 votes For and 677,861 votes Against.
  • Ratification of Auditors: The selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 110,533,253 votes For and 479,883 votes Against.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of shareholder vote tallies.

Key Facts for Investor Verification

  • Verify the tenure and background of the newly elected Class II directors (Imper, Muir, Yan) serving until 2029.
  • Confirm the level of shareholder support for executive compensation, noting that approximately 92.4% of votes cast were in favor.
  • Review the upcoming 2026 financial statements audited by Deloitte & Touche LLP to assess the company's financial health, as no metrics were included in this filing.
  • Note the significant number of broker non-votes (25,668,037) on director elections, which may indicate institutional holdings where brokers lacked discretionary voting power.

Notizie